Abbreviated name: D3 L-DOPA
Synonyms: DP-102
Compound class:
Synthetic organic
Comment: Chronic treatment with a substantially lower dose of deuterium-substituted L-DOPA (D3-L-DOPA), compared with L-DOPA (levodopa) produced equal anti-parkinsonian effects and reduced dyskinesia in 6-OHDA-lesioned rats [2]. This new rat study reports similar effect produced by D3-L-DOPA and selegiline plus L-DOPA, respectively, implying adjuvant MAO-B inhibitor treatment may not be necessary with D3-L-DOPA [1]. This compound was proposed for development by the Michael J Fox foundation but there is no ClinicalTrials.gov entry.
|
|
For advanced searching click here to open chemical structure editor
Similar Ligands ![]() |
|||||
|